Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare products, as well as for life science research; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology, which is used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Revenue projections:

Revenue projections for WAT
Revenue projections for WAT

WAT's revenues are expected to fall below last year's, and this forecast tends to raise concerns among investors. A revenue drop can negatively impact the company's profitability, making investors more cautious about their positions due to the risks of declining financial performance.

Financial Ratios:

currentRatio 1.861000
forwardPE 24.226135
debtToEquity 36.045000
earningsGrowth 0.000000
revenueGrowth 1.134000
grossMargins 0.563370
operatingMargins 0.094220
trailingEps 3.960000
forwardEps 16.562690

WAT's current ratio being 1.861 suggests the company will have no issues paying off its short-term debt. With sufficient cash reserves and current assets, WAT can easily cover its immediate liabilities, reflecting solid financial health.
WAT's Forward PE is positioned well, reflecting a favorable balance between stock price and earnings. The stock isn't overpriced, offering room for growth and making it a potentially rewarding investment as its value has room to rise further.
WAT's forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting WAT to generate stronger earnings compared to the previous financial year.

Price projections:

Price projections for WAT
Price projections for WAT

Over time, price projections for WAT have gradually increased, reflecting rising confidence in the company's future performance. This upward trend suggests analysts expect WAT to continue on a positive growth trajectory.

Insider Transactions:

Insider Transactions for WAT
Insider Transactions for WAT


There were 1 WAT sales transactions, at market price of 399.70001220703125.There were 2 transactions to buy Waters Corporation stock, with market price of 296.2799987792969.The higher volume of sells at WAT's current price levels could indicate potential for further price drops. If this selling trend continues, investors might expect the stock's value to decline as more shareholders exit their positions.

Recommendation changes over time:

Recommendations trend for WAT
Recommendations trend for WAT


Analysts have maintained a buy bias for WAT, which could prompt investors to consider the stock as a viable investment. With this positive outlook, WAT is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.